Compare Citius Pharmaceuticals Inc (CTXR) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NextEra Energy, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while NextEra Energy, Inc. trades at $88.88 (market cap $186.75B). The key difference: NextEra Energy, Inc. is far larger — about 12756.1× Citius Pharmaceuticals Inc's market cap, and NextEra Energy, Inc. pays a 2.78% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NEE | |
|---|---|---|
Market Cap | $14.64M | $186.75B |
Sector | Health | Utilities |
52-Week High | $1.82 | $97.88 |
52-Week Low | $0.53 | $69.77 |
Enterprise Value | $10.86M | $289.15B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
NextEra Energy (NEE) trades at $88.38, up 0.48% with neutral technical signals. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though revenue growth has been volatile. Recent earnings beat expectations in Q1 2026, with Q2 results due July 24. Analyst consensus is strongly bullish with $103 price target, while technical indicators show RSI at neutral levels with support at $87-88.
NEE presents a compelling utility investment with clean energy leadership and dividend growth potential, though faces risks from capital expenditure demands and regulatory uncertainty. The stock trades below analyst targets with institutional support, but investors should monitor execution on the Dominion deal and AI-driven power demand trends that could impact future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
